JP2004508415A - 抗脈管形成因子としてのｔｗｅａｋレセプターアゴニスト - Google Patents

抗脈管形成因子としてのｔｗｅａｋレセプターアゴニスト Download PDF

Info

Publication number
JP2004508415A
JP2004508415A JP2002526415A JP2002526415A JP2004508415A JP 2004508415 A JP2004508415 A JP 2004508415A JP 2002526415 A JP2002526415 A JP 2002526415A JP 2002526415 A JP2002526415 A JP 2002526415A JP 2004508415 A JP2004508415 A JP 2004508415A
Authority
JP
Japan
Prior art keywords
tweak
agonist
antibody
vegf
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002526415A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004508415A5 (enExample
Inventor
ブラウニング，　ジェフリー
バークリー，　リンダ
ジャクボウスキー，　アニエラ
ツェン，　ティモシー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of JP2004508415A publication Critical patent/JP2004508415A/ja
Publication of JP2004508415A5 publication Critical patent/JP2004508415A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
JP2002526415A 2000-09-14 2001-09-12 抗脈管形成因子としてのｔｗｅａｋレセプターアゴニスト Pending JP2004508415A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23235500P 2000-09-14 2000-09-14
PCT/US2001/028451 WO2002022166A2 (en) 2000-09-14 2001-09-12 Tweak receptor agonists as anti-angiogenic agents

Publications (2)

Publication Number Publication Date
JP2004508415A true JP2004508415A (ja) 2004-03-18
JP2004508415A5 JP2004508415A5 (enExample) 2008-10-23

Family

ID=22872776

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002526415A Pending JP2004508415A (ja) 2000-09-14 2001-09-12 抗脈管形成因子としてのｔｗｅａｋレセプターアゴニスト

Country Status (9)

Country Link
EP (2) EP2260867A1 (enExample)
JP (1) JP2004508415A (enExample)
AR (1) AR030721A1 (enExample)
AT (1) ATE515271T1 (enExample)
AU (2) AU8901901A (enExample)
CA (1) CA2422095A1 (enExample)
NZ (1) NZ525140A (enExample)
TW (1) TWI275399B (enExample)
WO (1) WO2002022166A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008531746A (ja) * 2005-03-07 2008-08-14 ジェネンテック・インコーポレーテッド Ｔｗｅａｋ及びｆｎ１４活性を調節するための方法及び組成物

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA004590B1 (ru) 1999-01-15 2004-06-24 Байоджен, Инк. Способ блокировки развития, или снижения тяжести, или проявлений заболевания "трасплантат против хозяина"
US7495086B2 (en) 1999-12-20 2009-02-24 Immunex Corporation TWEAK receptor
US6727225B2 (en) 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
CA2394015C (en) 1999-12-20 2013-11-05 Immunex Corporation Tweak receptor
AU2003224950B2 (en) * 2002-04-09 2006-09-14 Biogen Ma Inc. Methods for treating tweak-related conditions
JP4823060B2 (ja) 2003-07-24 2011-11-24 アムジェン インコーポレイテッド Ｔｗｅａｋ受容体のマルチマー化およびオリゴマー化可溶性断片に関する組成物および方法
EP1566636A1 (en) * 2004-02-23 2005-08-24 AXARON Bioscience AG Use of Tweak modulators and inhibitors for the treatment of neurological conditions
BRPI0509201A (pt) 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
AU2006214179A1 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
WO2006122187A2 (en) 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006130374A2 (en) 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Tweak binding antibodies
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
EP2545938A1 (en) 2007-08-03 2013-01-16 Abbott Biotherapeutics Corp. Therapeutic use of anti-tweak receptor antibodies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035061A2 (en) * 1997-02-12 1998-08-13 Abbott Laboratories Member of the tnf family useful for treatment and diagnosis of disease
WO2000042073A1 (en) * 1999-01-15 2000-07-20 Biogen, Inc. Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
WO2001045730A2 (en) * 1999-12-20 2001-06-28 Immunex Corporation Tweak receptor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773319A (en) 1971-12-16 1973-11-20 Fabcor Ind Inc Corrugated sheet inverting machine
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1998055508A2 (en) 1997-06-03 1998-12-10 Sagami Chemical Research Center HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS
JP2002536968A (ja) * 1999-01-29 2002-11-05 イムクローン システムズ インコーポレイティド Ｋｄｒに特異的な抗体およびその使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035061A2 (en) * 1997-02-12 1998-08-13 Abbott Laboratories Member of the tnf family useful for treatment and diagnosis of disease
WO2000042073A1 (en) * 1999-01-15 2000-07-20 Biogen, Inc. Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
WO2001045730A2 (en) * 1999-12-20 2001-06-28 Immunex Corporation Tweak receptor

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008531746A (ja) * 2005-03-07 2008-08-14 ジェネンテック・インコーポレーテッド Ｔｗｅａｋ及びｆｎ１４活性を調節するための方法及び組成物
JP2014111605A (ja) * 2005-03-07 2014-06-19 Genentech Inc Ｔｗｅａｋ及びｆｎ１４活性を調節するための方法及び組成物

Also Published As

Publication number Publication date
WO2002022166A9 (en) 2003-04-03
NZ525140A (en) 2005-10-28
TWI275399B (en) 2007-03-11
EP1317283A2 (en) 2003-06-11
WO2002022166A3 (en) 2002-08-01
EP1317283B1 (en) 2011-07-06
AU2001289019B2 (en) 2006-07-27
CA2422095A1 (en) 2002-03-21
WO2002022166A2 (en) 2002-03-21
EP2260867A1 (en) 2010-12-15
AU8901901A (en) 2002-03-26
ATE515271T1 (de) 2011-07-15
AR030721A1 (es) 2003-09-03

Similar Documents

Publication Publication Date Title
US7731963B2 (en) TWEAK receptor agonists as anti-angiogenic agents
US10934358B2 (en) Anti-DEspR inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
US5976534A (en) Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
EP2170366B1 (en) Use of tlr-2 antagonists for treatment of reperfusion injury and tissue damage
CN103261412B (zh) 抗人ccr7抗体、杂交瘤、核酸、载体、细胞、医药组合物和抗体固定化担载体
EP1317283B1 (en) Tweak receptor agonists as anti-angiogenic agents
US5620687A (en) Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
JP2003517829A (ja) Ｔｗｅａｋ受容体
AU2001289019A1 (en) Tweak receptor agonists as anti-angiogenic agents
SK98697A3 (en) Lymphotoxin-'alpha'/'beta' complexes and anti-lymphotoxin-beta receptor antibodies as anti-tumor agents
US20100279307A1 (en) Angiogenesis Inhibiting Molecules, Their Selection, Production and Their Use in the Treatment of Cancer
CN1890567B (zh) 血管发生抑制分子及其在癌症治疗和诊断中的用途
JP2005508298A (ja) アテローム性動脈硬化症及び他の炎症性疾患を処置する方法
JP2944218B2 (ja) Ｐｄｇｆレセプタに対する抗体を使用した脈管内膜過形成の阻害
JP2003529370A (ja) 血管浸透性に対する有害な作用を有さないｖｅ−カドヘリンに対する拮抗薬抗体
KR20100134677A (ko) Ｇｐｖｉ의 억제에 의한 암의 예방 및 치료 방법
WO2024002226A1 (zh) 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
US20020044933A1 (en) Inhibition of intimal hyperplasia using antibodies to PDGF receptors
RINI et al. Ligand-Binding Agents
HK1183880A (en) Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080904

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080904

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110506

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111102